About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Media Library
Philogen in the news
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Publications
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
OncoFAP Radio Conjugates (Imaging)
OncoFAP Radio Conjugates (Therapy)
OncoFAP-GlyPro-MMAE
OncoACP3 (Imaging)
OncoACP3 (Therapy)
OncoCAIX
Press Releases & Media
Press Releases
Events
Philogen in the news
Media Library
Work with us
Careers
Partnering
News & Events
2023
,
Investors
,
Press Releases
20 marzo 2023 – Aggiornamento sul programma di acquisto di azioni proprie
Mar 20, 2023
More details
Last News & Events
Jan
2019
23
Philogen announces collaboration with Celgene
Jan
2019
8
Philogen Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma
« Previous
1
…
120
121
122
123
124
…
132
Next »
